Good Investment Books summaries by us,

Psychology of money,
https://t.co/R09FIfmMxL

Zebra in a lion country,
https://t.co/56AfJjY8dP

Quality Investing,
https://t.co/2y1fCgydLh

The Most Important Thing,
https://t.co/kg49bAWQQD

Capital

Thread on Astec Lifesciences Ltd 🧵

Market cap: 1996.7 crores.
Revenues: 522.61 crores.
P/E: 27.62
P/B: 7.0
ROCE: 20.44%
ROE: 21.24%

Here we go👇

ASTEL is a niche chemical company focused on triazole fungicides & on proprietary off-patent products in the CRAMS segment;

1/25

New products in the herbicides segment should drive growth in the CRAMS space.

Leader in triazole fungicides:

Tebuconazole and Propiconazole currently form a major part of ASTEL’s enterprise business while it is capable of venturing into newer products given strong

2/25

technical knowledge in triazole chemistry.

Newer mixtures/geographies to drive growth in Enterprise business:

Triazole fungicides have been losing market share over the years as new products (SDHI fungicides) have proved to be a replacement;

3/25

However, with a few SDHI (succinate dehydrogenase inhibitors) products facing resistance in some geographies and given strong forecasts for this segment, triazole fungicides are likely to benefit–albeit in a limited way–from their inclusion in a

4/25

mixture of products (with some SDHIs).

ASTEL is setting up a new herbicide plant To diversify its product concentration from the triazole fungicide segment.

New R&D Centre to aid diversification:

Would help develop new processes into various chemistries like fluorine;

5/25